RADX BLUEPRINT MEDTECH TRANSLATOR COHORT 2 - COMMERCIALIZATION CENTER - HEAL

The Blueprint MedTech program is an NIH incubator that aims to support the innovators by accelerating the development of cutting-edge medical devices for diagnosing and treating disorders of the nervous system. The mission of the program is to catalyze the translation of novel technologies from early-stage development to readiness for first-in-human clinical studies. By providing non-dilutive funding and access to essential resources, including planning support, design and testing services, and expert consultations on regulatory and commercialization issues, the program seeks to facilitate the translation of novel technologies to readiness for first-in-human clinical studies. Its goal is to enhance patient access to safe and effective medical devices while attracting further investment from industry and government. This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative bolsters research across NIH to (1) improve treatment for opioid misuse and addiction and (2) enhance pain management. Project Number: 75N92022D00013-0-759202500001-2 | Fiscal Year: 2025 | NIH Institute/Center: National Heart Lung and Blood Institute (NHLBI) | Institution: VENTUREWELL, HADLEY, MA | Award Amount: $511,206 | Activity Code: N02 View on NIH RePORTER: https://reporter.nih.gov/project-details/75N92022D0001307592025000012